Vistagen reports FY 2023 net loss $59.2M; positive fasedienol, itruvone clinical updates

Vistagen Therapeutics, Inc.

Net loss of $59.2M for FY ended March 31, 2023, vs $48.7M prior year; cash $16.6M.
Positive FDA feedback supports LSAS as primary endpoint for fasedienol Phase 3 FEARLESS program in SAD.
Successful U.S. Phase 1 study of itruvone (PH10) enables Phase 2B development in MDD; Fast Track granted.
PH80 nasal spray showed statistically significant reduction in hot flashes vs placebo in Phase 2A (p<.001).
Company pursuing global partnerships to advance six CNS product candidates.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported financial results for fiscal year ended March 31, 2023.

Period: fiscal year ended March 31, 2023
Result: reported results

Exact text from the filing

today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-018765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.